Secondary Logo

Journal Logo

April 2016 - Volume 27 - Issue 4
pp: 269-372

An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors

Awada, Ahmad; Campone, Mario; Varga, Andrea; More

Anti-Cancer Drugs. 27(4):342-348, April 2016.

Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors

Saponara, Maristella; Gatto, Lidia; Di Nunno, Vincenzo; More

Anti-Cancer Drugs. 27(4):353-363, April 2016.